Phaseline

Targets › CACNB4

CACNB4 (Voltage-dependent L-type calcium channel subunit beta-4): drug programs, companies and trials

4 programs from 4 companies in 46 trials: 18 Phase 2, 13 Phase 4, 10 Phase 1, 5 Phase 3; Neurology, Oncology, Other; next expected readout Nov 2026.

The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting. (UniProt, O00305)

Open in Phaseline: the race on CACNB4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
ViatrisGabapentin
Voltage-gated calcium channel modulator
Ion channels, CACNB4, CACNB2, CACNB1, CACNB3Phase 4Healthy; Tonsillitis; Dental Pain and Sensation Disorder; Pain, Postoperative …Jan 2027
University of Texas at AustinGabapentin Enacarbil
Voltage-gated calcium channel modulator
Ion channels, CACNB4, CACNB2, CACNB1, CACNB3Phase 4Alzheimer Disease–
Brainfarma Industria Química e Farmacêutica S/APregabalin
Voltage-gated calcium channel modulator
Ion channels, CACNB4, CACNB2, CACNB1, CACNB3Phase 3Diabetic Neuropathy; Shoulder Arthropathy; Pregabalin; Diabetic Pruritus …Jun 2027

Conditions

Alcohol Use Disorder (3) Head and Neck Squamous Cell Carcinoma (3) Pain, Postoperative (3) Alzheimer Disease (1) Diabetic Neuropathy (1) Shoulder Arthropathy (1) Pregabalin (1) Diabetic Pruritus (1) Rotator Cuff Repairs (1) Early-stage Breast Cancer (1) Painful Peripheral Neuropathy (1) Acute Kidney Injury (1)

Modalities

small molecule (4)

Companies

University of Texas at Austin (1) Brainfarma Industria Química e Farmacêutica S/A (1) University of Pennsylvania (1) Viatris (1)

Related targets

Ion channels (4) CACNB2 (4) CACNB1 (4) CACNB3 (4) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.